Sound Biologics 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
100 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
NCT07004335: Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Not yet recruiting
4
40
RoW
Iparomlimab and Tuvonralimab Injection plus Bevacizumab
Hebei Medical University Fourth Hospital, Qilu Pharmaceutical Co., Ltd.
PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
12/28
01/29
ChiCTR2500098165: An exploratory clinical study on neoadjuvant treatment of hepatocellular carcinoma with Iparomlimab and Tuvonralimab Injection combined with lenvatinib

Recruiting
4
30
 
Iparomlimab and Tuvonralimab Injection(5mg/kg, on day 1 and day 21 of each cycle) combined with Lenvatinib (dose of 8mg for patients with body weight < 60kg, and 12mg for those with body weight >= 60kg, once daily, with a 21-day cycle) was used for neoadjuvant treatment for 2 cycles.
Suibei People's Hospital; Suibei People's Hospital, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2500101131: Iparomlimab and Tuvonralimab Injection (QL1706) Combined with Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) with High Risk of Recurrence: A Multicenter, Open-Label, Single-Arm, Phase II Study

Not yet recruiting
4
60
 
Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab
Xuzhou Medical University Affiliated Hospital; Xuzhou Medical University Affiliated Hospital, Self-funding
Hepatocellular Carcinoma
 
 
ChiCTR2500102932: A single-arm, phase II exploratory study of iparomlimab and tuvonralimab combined with platinum-based chemotherapy and Anlotinib in the treatment of advanced or metastatic non-small cell lung cancer with SMARCA4-deficient

Not yet recruiting
4
23
 
iparomlimab and tuvonralimab combined with platinum-based chemotherapy and Anlotinib
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute), Qilu Pharmaceutical Co. Ltd
SMARCA4 Deletion of advanced or metastatic non-small cell lung cancer
 
 
ChiCTR2500100119: A Single-Arm, Open Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination with Apatinib Mesylate and Capecitabine for Advanced Second-Line and Higher Esophageal Cancer

Not yet recruiting
4
30
 
Drug interventions
Taizhou People's Hospital; Taizhou People's Hospital, self-finance
Esophageal cancer
 
 
ChiCTR2500100631: A single-center, single-arm, Phase Ib/II trial of Iparomlimab and Tuvonralimab combined with vinorelbine metronomic chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer who have failed first-line treatment with PD-1/PD-L1 inhibitor and a combination regimen containing platinum

Not yet recruiting
4
22
 
Iparomlimab and Tuvonralimab combined with vinorelbine metronomic chemotherapy
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Qilu-pharma
Non-small cell lung cancer
 
 
ChiCTR2500100876: Efficacy and safety of neoadjuvant chemotherapy plus Iparomlimab and Tuvonralimab for locally advanced cervical cancer: A multicenter, randomized, double-blind, parallel-controlled study

Recruiting
4
76
 
Paclitaxel for injection combined with cisplatin chemotherapy and Iparomlimab and Tuvonralimab Injection, for 3 cycles, with 21 days as one cycle; Paclitaxel for injection combined with cisplatin chemotherapy and the simulant of Iparomlimab and Tuvonralimab Injection, for 3 cycles, with 21 days as one cycle
The Seventh Medical Center of Chinese PLA General Hospital; The Seventh Medical Center of Chinese PLA General Hospital, Qilu Pharmaceutical Co., Ltd.
cervical cancer
 
 
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting
3
498
RoW
QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
METASTATIC CERVICAL CANCER
09/24
07/25
QL1706-307, NCT06686576: A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
288
RoW
QL1706, CAPEOX
Qilu Pharmaceutical Co., Ltd.
Colon Cancer
12/30
12/30
NCT06789796: a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not yet recruiting
3
636
NA
Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604, placebo for Iparomlimab and Tuvonralimab (QL1706)
Qilu Pharmaceutical Co., Ltd.
Small-cell Lung Cancer
03/28
03/30
NCT06749899: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
INVIGORATE, NCT07002346: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Not yet recruiting
3
226
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Bevacizumab, carboplatin, Paclitaxel
Tongji Hospital, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center ( FUSCC ), Sun Yat-sen University Cancer Center (SUSUCC), Peking University Cancer Hospital & Institute, Peking University People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, The Second Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Fudan University, Renmin Hospital of Wuhan University, Zhejiang Provincial People's Hospital, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Shanghai First Maternity and Infant Hospital, Hubei Cancer Hospital, Sir Run Run Shaw Hospital, Wuhan Central Hospital, Zhejiang Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, Henan Cancer Hospital, Jiangsu Cancer Institute & Hospital, The International Peace Maternity & Child Health Hospital of China welfare institute, Women's Hospital School Of Medicine Zhejiang University, Wuhan Union Hospital, China, First Affiliated Hospital of Zhejiang University
Ovarian Clear Cell Carcinoma
06/27
06/29
DUBHE-L-303, NCT05690945: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Recruiting
3
608
RoW
QL1706, PSB205, Tilesizumab, BGB-108
Qilu Pharmaceutical Co., Ltd.
Lung Cancer
06/29
12/29
NCT07025239: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Not yet recruiting
3
430
NA
QL1706, Bevacizumab, Oxaliplatin, Capecitabine, Placebo
Qilu Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
07/28
07/29
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting
3
632
RoW
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
08/27
05/29
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2/3
460
RoW
QL1706, Carrelizumab, Gemcitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/24
12/24
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2/3
668
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab
Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
09/27
09/27
NCT05557565: A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Recruiting
2
150
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Cervical Cancer
10/22
06/23
DUBHE-C-204, NCT05179317: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Active, not recruiting
2
60
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Cervical Cancer
12/22
12/23
DUBHE-L-201, NCT05329025: A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Active, not recruiting
2
100
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Non-small-cell Lung Cancer
01/24
01/24
NCT05309629: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Completed
2
40
RoW
QL1706, Carboplatin, Etoposide
Qilu Pharmaceutical Co., Ltd.
Extensive-stage Small-cell Lung Cancer
02/23
12/24
QL1706-IIT-02, NCT05490719: A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Recruiting
2
39
RoW
QL1706, Radiation, Taxol, Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
09/24
09/25
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Recruiting
2
60
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine
Qilu Pharmaceutical Co., Ltd.
Colorectal Carcinoma
03/24
09/25
NCT06313970: First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Not yet recruiting
2
50
NA
QL1706, Nab-paclitaxel, Gemcitabine, Bevacizumab
Fudan University
Pancreatic Cancer
04/25
04/26
QUEEN-Neo, NCT06404463: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting
2
76
NA
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin, Cyclophosphamide, Epirubicin
Fudan University
Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
11/25
11/30
QUEEN-Dream, NCT06404736: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Not yet recruiting
2
73
RoW
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
Fudan University
Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
11/25
11/30
QLS31905-202, NCT06446388: Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting
2
360
RoW
QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
06/26
12/27
NCT06509971: A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Not yet recruiting
2
39
NA
QL1706, bevacizumab, albumin-binding paclitaxel
West China Second University Hospital
Platinum-resistant Recurrent Ovarian Cancer
02/26
06/26
NCT06786026: QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Recruiting
2
60
RoW
bevacizumab, QL1706, Nab paclitaxel
Fudan University
TNBC, Triple Negative Breast Cancer
09/25
12/28
QLMA-EdC-IIT-001, NCT06751277: QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Not yet recruiting
2
26
RoW
QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
xiang yang, Qilu Pharmaceutical Co., Ltd.
Recurrent or Metastatic Endometrial Cancer
12/26
07/27
NCT06750861: QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC

Not yet recruiting
2
30
RoW
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Adenocarcinoma
06/26
12/26
STAR-03, NCT06829797: A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
2
96
NA
Neoadjuvant Therapy(QL1706+SOX Chemotherapy), Neoadjuvant Therapy(SOX Chemotherapy), Radical surgery (D2), Drug: Adjuvant therapy(QL1706+SOX chemotherapy), Drug: Adjuvant therapy(SOX chemotherapy)
Shandong Provincial Hospital
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
02/28
02/28
NCT06942416: Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Recruiting
2
36
RoW
Paclitaxel and Cisplatin/ Carboplatin, Iparomlimab and Tuvonralimab, Radiotherapy
Shandong Cancer Hospital and Institute
Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic
07/26
12/28
QL1706-305, NCT06852456: QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
30
NA
Iparomlimab and Tuvonralimab (QL1706)Injection, Paclitaxel, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
12/30
12/34
Mizar-CC-II-003, NCT06882447: A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Not yet recruiting
2
35
NA
Trial drug: QL1706, HPV 9-valent vaccine
Northern Jiangsu People's Hospital
Cervical Cancer Stage IVB
12/27
12/28
NCT06787183: SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Not yet recruiting
2
42
RoW
Short course radiotherapy, Capecitabine, Oxaliplatin, QL1706
Fujian Cancer Hospital
Locally Advanced Rectal Cancer With Liver Metastases
12/27
12/27
NCT06884982: An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Not yet recruiting
2
30
NA
QL1706 Plus Lenvatinib
Northern Jiangsu People's Hospital
HCC - Hepatocellular Carcinoma
09/27
09/28
QIBA-CER-003, NCT06878222: Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Recruiting
2
35
RoW
Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery, Fertility-preserving surgery
Obstetrics & Gynecology Hospital of Fudan University
Cervical Cancers
03/28
03/30
SEARCH, NCT06932068: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Recruiting
2
77
RoW
Iparomlimab and Tuvonralimab (QL1706), Oxallplation, Capectitabine Tablets
Qilu Hospital of Shandong University
HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
10/26
10/27
NCT06801665: FMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis

Not yet recruiting
2
30
NA
FMT+QL1706+Bevacizumab+XELOX
Hua Jiang
Colon Cancer Liver Metastases
02/27
02/27
NCT06930118: The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Recruiting
2
60
RoW
chidamide, regorafenib, and iparomlimab/tuvonralimab
Shanghai Changzheng Hospital
Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer
04/27
09/27
NCT06908382: Neoadjuvant QL1706 Therapy for ESCC

Recruiting
2
32
RoW
Iparomlimab and Tuvonralimab Injection
Shandong Provincial Hospital
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
12/26
12/28
NCT06911684: Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Recruiting
2
88
RoW
lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
Sun Yat-sen University
Rectal Cancer Patients
04/26
12/31
Spring, NCT06892925: QL1706 Combined with Lenvatinib and GEMOX As First - Line Treatment for Unresectable Biliary Tract Tumors

Not yet recruiting
2
59
RoW
QL1706, Lenvatinib, GEMOX
Eastern Hepatobiliary Surgery Hospital
Biliary Tract Tumors
04/26
04/29
NCT06958484: Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Not yet recruiting
2
60
NA
Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
The Affiliated Hospital of Xuzhou Medical University
HCC - Hepatocellular Carcinoma, Adjuvant Treatment
10/26
12/27
NCT06864013: SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Not yet recruiting
2
116
RoW
Experimental, Control
First Affiliated Hospital of Zhejiang University
Locally Advanced Rectal Cancer (LARC)
12/29
12/29
QLPPEC/GOG-003, NCT06917092: QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

Recruiting
2
30
RoW
QL1706 combined with chemotherapy ± Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Endometrial Adenocarcinoma, Endometrial Cancer
04/27
04/30
NCT06951997: QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Not yet recruiting
2
33
NA
QL1706, Chidamide, Gemcitabine, Nab-paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Metastatic Pancreatic Cancer
05/27
12/27
Neo-Color, NCT06949111: Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（）

Recruiting
2
128
RoW
radiotherapy, CAPOX, Capecitabine, Iparomlimab and Tuvonralimab Injection
Hebei Medical University Fourth Hospital
Colon Cancer
02/27
03/29
NCT06967103: QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Not yet recruiting
2
238
NA
QL1706, Nab-PE
Henan Cancer Hospital
Breast Cancer, HR+/HER2- Breast Cancer
05/27
05/29
NCT07026422: Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Recruiting
2
54
RoW
Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy
Shandong Cancer Hospital and Institute
Rectal Malignant Neoplasms
11/26
05/28
NCT06986057: Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Not yet recruiting
2
28
NA
Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy
Shandong Tumor Hospital
Cervical Cancer, Neoadjuvant Therapy
07/26
12/26
NCT07007728: Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Not yet recruiting
2
54
RoW
Iparomlimab/Tuvonralimab, Bevacizumab + CAPEOX, Surgical resection ± ablation or stereotactic radiotherapy (if applicable)
Peking University Cancer Hospital & Institute
Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
12/26
12/26
NCT07014150: Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Not yet recruiting
2
30
RoW
Lenvatinib, Iparomlimab and Tuvonralimab
Peking Union Medical College Hospital
Hepatocellular Carcinoma Resectable
05/27
05/27
SFRT、RT, NCT06936748: SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

Not yet recruiting
2
30
RoW
Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab
Second Affiliated Hospital of Nanchang University, Qilu Pharmaceutical Co., Ltd.
Cancer
06/28
06/29
NCT07009145: QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Not yet recruiting
2
22
RoW
QL1706, Bevacizumab
Qianfoshan Hospital, Linyi Tumour Hospital, Shandong Provincial Hospital, Qingdao Central Hospital
Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
06/26
12/27
NCT07005583: Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
2
46
RoW
QL1706 Plus Olaparib
Tianjin Medical University Cancer Institute and Hospital
Triple-Negative Breast Cancer (TNBC)
05/27
05/30
NCT06939855: QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
45
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Sun Yat-sen University
Bone and Soft Tissue Tumors
05/27
05/28
NCT07035808: a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .

Not yet recruiting
2
46
NA
2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy
Zhejiang Cancer Hospital, Cancer Hospital of The University of Chinese Academy of Sciences, Cancer Center of the First Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nanchang University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, People's Hospital of Quzhou, First Affiliated Hospital of Ningbo University, Wenzhou Central Hospital, Jinhua Municipal Central Hospital, First Hospital of Zhejiang University, First Affiliated Hospital of Zhejiang University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University
Cervical Cancer Stage IVA, Cervical Cancer Metastatic
12/28
12/29
NCT07041788: Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Not yet recruiting
2
25
RoW
Iparomlimab and Tuvonralimab Injection
Second Affiliated Hospital of Nanchang University, Qilu Pharmaceutical Co., Ltd.
Cancer
07/28
07/30
NCT06897046: Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Not yet recruiting
2
90
NA
QL1706, QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer (NSCLC), II-IIIB
02/27
05/27
QICE-ESCC, NCT07049185: QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
35
NA
QL1706 Plus Celecoxib Group
Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
03/27
09/27
NCT07045805: Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Not yet recruiting
2
66
NA
QL1706 combined with paclitaxel and bevacizumab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Gastric Cancer (GC)
07/27
03/28
CCGLC-017, NCT06954116: Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Not yet recruiting
2
26
RoW
Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
Tongji Hospital, Qilu Pharmaceutical Co., Ltd.
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
12/28
04/29
ChiCTR2500097658: A Single-Center, Single-Arm Clinical Study of Iparomlimab and Tuvonralimab Injection as Monotherapy for Advanced Hepatocellular Carcinoma Beyond first-Line Therapy

Not yet recruiting
2
30
 
Q3W, QL1706 at a dose of 5mg/kg is administered on the first day of each cycle. The dosing time window can be ±3 days. However, within 72 hours before each administration, except for imaging examinations, the subjects must complete all the examinations including vital signs, physical examination, laboratory tests, and ECOG PS score.
Taixing People's Hospital; Taixing People's Hospital, Self-finance
Hepatocellular carcinoma
 
 
ChiCTR2500096704: Iparomlimab/tuvonralimab combined with regorafenib for first-line failure of rare tumors of the digestive system

Not yet recruiting
2
91
 
Iparomlimab/tuvonralimab，regorafenib; Iparomlimab/tuvonralimab,regorafenib; Iparomlimab/tuvonralimab,regorafenib
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-raised
Advanced rare gastrointestinal tumors (anal squamous cell carcinoma, peritoneal mesothelioma, and peritoneal metastatic cancer) that have failed first-line or above treatment
 
 
ChiCTR2500103154: Clinical study on the treatment of advanced melanoma with Iparomlimab and Tuvonralimab combined with chemotherapy and bevacizumab

Not yet recruiting
2
26
 
Iparomlimab and Tuvonralimab+albumin-bound paclitaxel + carboplatin + bevacizumab
Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Self-raised
Melanoma
 
 
ChiCTR2500101134: Iparomlimab and tuvonralimab in combination with neoadjuvant chemotherapy in treatment-naive advanced epithelial ovarian cancer: a single-arm, phase II study

Not yet recruiting
2
35
 
Iparomlimab and tuvonralimab antibody combined with TC
Sichuan Cancer Hospital; Sichuan Cancer Hospital, self funded
advanced epithelial ovarian
 
 
ChiCTR2500102923: Iparomlimab and Tuvonralimab Injection in combination with nab-paclitaxel and carboplatin for the treatment of inoperable or recurrent metastatic treatment-naive thymic carcinoma prospective, single-arm, phase II exploratory study

Not yet recruiting
2
40
 
Immunotherapy + chemotherapy
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute), Self-selected project (self-raised)
Inoperable or recurrent and metastatic newly diagnosed thymic carcinoma
 
 
ChiCTR2500101129: ​Efficacy and Safety of Iparomlimab/Tuvorlimab (QL1706) in Treating Intermediate Trophoblastic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial​​

Not yet recruiting
2
20
 
QL1706; QL1706 plus chemotherapy
Peking Union Medical College Hospital; Peking Union Medical College Hospital, National Key R&D Program (China)​​
Intermediate trophoblastic tumors
 
 
ChiCTR2500103468: A single-arm, multicenter, phase II clinical study of Tuvonralimab/Iparomlimab and docetaxel in patients with advanced non-small-cell lung cancer who have progressed following immune checkpoint inhibitor

Not yet recruiting
2
43
 
Treated with Otto combination antibody (5 mg/kg) plus docetaxel (60-75 mg/m2) every 3 weeks (Q3W)
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Projects entrusted by enterprises and public institutions
Non-small-cell lung cancer
 
 
ChiCTR2500102974: A single arm, single center study to explore the efficacy and safety of Iparomlimab and Tuvonralimab Injection plus Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2
24
 
Iparomlimab and Tuvonralimab Injection
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Self-financed
Triple Negative Breast Cancer (TNBC)
 
 
ChiCTR2500102587: Iparomlimab and Tuvonralimab as second-line treatment in recurrent/metastatic squamous cell carcinoma of the head and neck: a prospective, single-arm, phase II clinical study

Not yet recruiting
2
34
 
Iparomlimab and Tuvonralimab, 5mg/kg,q3w
Pingxiang People's Hospital; Pingxiang People's Hospital, Qilu Pharmaceutical Co., Ltd.
Recurrent/metastatic squamous cell carcinoma of the head and neck
 
 
ChiCTR2500103181: A single-arm phase II multicenter clinical study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab in the first-line treatment of MSI-H/dMMR or POLE/POLD1 mutated metastatic colorectal cancer

Not yet recruiting
2
55
 
Iparomlimab and Tuvonralimab Injection; Iparomlimab and Tuvonralimab Injection
Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, Subject of your choice (self-supporting)
Metastatic colorectal cancer with MSI-H/dMMR or POLE/POLD1 mutations
 
 
NCT05262413: A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Not yet recruiting
1/2
60
NA
QL1706 Plus Lenvatinib, PSB205
Qilu Pharmaceutical Co., Ltd.
Advanced Renal Cell Carcinoma
07/23
07/24
NCT05603039: A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Recruiting
1/2
80
RoW
QL1706, QL1604, Bevacizumab
Qilu Pharmaceutical Co., Ltd.
Advanced Liver Cancer
12/23
12/23
NCT06746961: Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

Not yet recruiting
1/2
49
NA
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, MK-7902, E7080, LENVIMA
The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
07/26
08/27
NCT06809530: Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Recruiting
1/2
34
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta)
Guangzhou Medical University
Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid Tumors
06/26
07/26
QL-GasC-QIBA-1001, NCT06766305: QL1706 Combined With SOX Used in Theperioperative Treatment

Recruiting
1/2
54
RoW
QL1706 combined with SOX
Xiangdong Cheng
Gastric Cancers, Esophagogastric Junction Cancers
02/26
06/31
NCT06941766: Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Recruiting
1/2
20
RoW
QL1706, Chemotherapy
Peking Union Medical College Hospital, Shengjing Hospital, Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital), Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Henan Cancer Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, The First Affiliated Hospital of Xiamen University, Sichuan Cancer Hospital and Research Institute
Intermediate Trophoblastic Tumor
04/27
04/28
NCT06949761: A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Not yet recruiting
1/2
240
NA
QLC1101+QL1203, QLC1101+QL2107, QLC1101+QL1706, QLC1101+docetaxel
Qilu Pharmaceutical Co., Ltd.
Solid Tumor
09/26
06/27
NCT06602063: Surgery for Relapsed Ovarian Cancer in Precision

Not yet recruiting
1/2
33
RoW
surgery/chemotherapy, Iparomlimab/Tuvonralimab
Shanghai Gynecologic Oncology Group, Shanghai Zhongshan Hospital, Tongji Hospital
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/30
06/30
QL1706-102, NCT05171790: A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Active, not recruiting
1b
419
RoW
QL1706 injection, PSB205 injection
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/21
12/23
NCT03986606: A Study of PSB205 in Subjects With Advanced Solid Tumors

Recruiting
1
64
US
PSB205
Qilu Puget Sound Biotherapeutics (dba Sound Biologics), Pharmaceutical Research Associates
Neoplasm Malignant
02/21
07/21
NCT04296994: A Study of QL1706 in Subjects With Advanced Malignant Tumor

Active, not recruiting
1
99
RoW
QL1706, PSB205
Qilu Pharmaceutical Co., Ltd.
Advanced Malignant Tumor
12/21
12/23
QLMA-HCC-IIT-101, NCT06822985: QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Not yet recruiting
1
21
RoW
QL1706
Wan-Guang Zhang, Qilu Pharmaceutical Co., Ltd.
HCC - Hepatocellular Carcinoma
08/26
08/26
NCT06931873: Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer

Not yet recruiting
1
60
NA
SCRT+Capoex+QL706, LCRT+Capoex+QL706
Changhai Hospital
Rectal Cancer
03/28
03/35
NCT06760676: A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Not yet recruiting
1
90
NA
Pulsed low dose rate radiotherapy (PLDR), Alpaloritovorelli antibodies
Anhui Provincial Hospital, Qilu Pharmaceutical Co., Ltd.
Esophageal Cancer, Non Small Cell Lung Cancer, Cervical Cancer
05/27
07/27
ChiCTR2500101088: A Prospective, Open-label, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Injection +- TKI Agents in Advanced Hepatocellular Carcinoma Patients Previously Treated with Immune Checkpoint Inhibitors

Not yet recruiting
1
20
 
paromlimab and Tuvonralimab Injection:5mg/kg, on day 1 , day 21 of each cycle ; Tyrosine kinase inhibitors (TKIs): Administration at the investigator's discretion.
Huaibei People's Hospital; Huaibei People's Hospital, Self-funded
Hepatocellular carcinoma
 
 
ChiCTR2500103253: An Open-label, Single-arm, Single-center Clinical Study of Iparomlimab and Tuvorralimab (QL1706) in Combination with Lenvatinib as First-line Treatment for Hepatocellular Carcinoma (HCC)

Not yet recruiting
1
30
 
paromlimab and Tuvonralimab Injection:5mg/kg, on day 1 , day 21 of each cycle ; Lenvatinib: oral, once a day, based on patient's weight (<=60 kg: 8 mg; >60 kg: 12 mg).
The First Affiliated Hospital of Anhui University of Technology; The First Affiliated Hospital of Anhui University of Technology, Self-funded
Hepatocellular carcinoma
 
 
ICT-HCC, NCT06893887: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
FOLFOX4, Adebrelimab, Apatinib, Icaritin, SHR-1701, QL1706, Bevacizumab, HAIC, Local treatment, The original treatment regimen
Nanjing Tianyinshan Hospital
Hepatocellular Carcinoma(HCC)
03/27
03/28
NCT07046780: A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Not yet recruiting
N/A
90
RoW
Observation arm
PENG YUAN
Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
07/27
12/27
ChiCTR2500099628: Efficacy and safety evaluation of Iparomlimab and Tuvonralimab combined with Anlotinib in treatment of small-cell lung cancer for second-line and above: A Single Arm, Single-Center, Open-Label Trial.

Not yet recruiting
N/A
35
 
the combination antibody of Iparomlimab and Tuvonralimab at a dose of 5 mg/kg is administered intravenously once every three weeks, in combination with Anlotinib taken orally at 12 mg/day for 14 days, repeated every three weeks.
The Second Affiliated Hospital of Zhejiang University School of Medicine; the department of respiratory medicine, Qilu Pharmaceutical Co., Ltd.
Lung cancer
 
 
ChiCTR2500099552: Clinical study of short-term radiotherapy followed by Iparomlimab and Tuvonralimab Injection combined with TAS-102 (Suyuan) and oxaliplatin neoadjuvant therapy for locally advanced rectal cancer

Not yet recruiting
N/A
30
 
SBRT+ Iparomlimab and Tuvonralimab Injection +TAS-102 + oxaliplatin
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Qilu Pharmaceutical Co., Ltd
Rectal cancer
 
 
ChiCTR2500095948: A single-arm, open-label, multicenter clinical study of Aplalitovorali (QL1706, anti-PD1/CTLA-4 combination antibody) in combination with chemotherapy for the treatment of recurrent or metastatic endometrial cancer

Not yet recruiting
N/A
26
 
Atezo combination antibody combined with chemotherapy
Peking Union Medical College Hospital; Peking Union Medical College Hospital, A single-arm, open-label, multicenter clinical study of Aplalitovorali (QL1706, anti-PD1/CTLA-4 comb
Newly diagnosed recurrent or metastatic endometrial cancer.
 
 
ChiCTR2500102918: Neo-adjuvant QL1706 combined with chemotherapy for stage II-III non-small cell lung cancer(NSCLC): A single-arm, phase II study

Not yet recruiting
N/A
30
 
QL1706 (5mg/kg, iv, q3w) combined with chemotherapy as neo-adjuvant treatment for three cycles
Zhangzhou Municipal Hospital of Fujian Province; Zhangzhou Municipal Hospital of Fujian Province, Qilu Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2500101828: A real-world study on the treatment of advanced first-line gastric / esophageal cancer with low expression of PD-L1 with Iparomlimab and Tuvonralimab Injection

Not yet recruiting
N/A
200
 
None; None
Henan Cancer Hospital; Henan Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Gastric / esophageal cancer
 
 
ChiCTR2500101824: A real-world study of Iparomlimab and Tuvonralimab in the treatment of digestive tract tumors after previous first-line immunotherapy resistance

Recruiting
N/A
148
 
None
Henan Cancer Hospital; Henan Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Gastrointestinal cancer
 
 
ChiCTR2500102269: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Not yet recruiting
N/A
580
 
PD-1/CTLA-4 bi-specific Antibody combined with chemoradiotherapy; induction chemotherapy followed by systemic therapy/RT
Sun Yat-sen University Cancer Prevention and Treatment Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen University Cancer Prevention and Treatment Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Research Institute), Self-selected topic (self-sponsored)
Advanced nasopharyngeal carcinoma in a high-risk localized area
 
 
PSB202 / Sound Biologics
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Recruiting
1a/1b
110
US, RoW
PSB202
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
07/23
01/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
NCT07004335: Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Not yet recruiting
4
40
RoW
Iparomlimab and Tuvonralimab Injection plus Bevacizumab
Hebei Medical University Fourth Hospital, Qilu Pharmaceutical Co., Ltd.
PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
12/28
01/29
ChiCTR2500098165: An exploratory clinical study on neoadjuvant treatment of hepatocellular carcinoma with Iparomlimab and Tuvonralimab Injection combined with lenvatinib

Recruiting
4
30
 
Iparomlimab and Tuvonralimab Injection(5mg/kg, on day 1 and day 21 of each cycle) combined with Lenvatinib (dose of 8mg for patients with body weight < 60kg, and 12mg for those with body weight >= 60kg, once daily, with a 21-day cycle) was used for neoadjuvant treatment for 2 cycles.
Suibei People's Hospital; Suibei People's Hospital, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2500101131: Iparomlimab and Tuvonralimab Injection (QL1706) Combined with Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) with High Risk of Recurrence: A Multicenter, Open-Label, Single-Arm, Phase II Study

Not yet recruiting
4
60
 
Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab
Xuzhou Medical University Affiliated Hospital; Xuzhou Medical University Affiliated Hospital, Self-funding
Hepatocellular Carcinoma
 
 
ChiCTR2500102932: A single-arm, phase II exploratory study of iparomlimab and tuvonralimab combined with platinum-based chemotherapy and Anlotinib in the treatment of advanced or metastatic non-small cell lung cancer with SMARCA4-deficient

Not yet recruiting
4
23
 
iparomlimab and tuvonralimab combined with platinum-based chemotherapy and Anlotinib
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute), Qilu Pharmaceutical Co. Ltd
SMARCA4 Deletion of advanced or metastatic non-small cell lung cancer
 
 
ChiCTR2500100119: A Single-Arm, Open Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination with Apatinib Mesylate and Capecitabine for Advanced Second-Line and Higher Esophageal Cancer

Not yet recruiting
4
30
 
Drug interventions
Taizhou People's Hospital; Taizhou People's Hospital, self-finance
Esophageal cancer
 
 
ChiCTR2500100631: A single-center, single-arm, Phase Ib/II trial of Iparomlimab and Tuvonralimab combined with vinorelbine metronomic chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer who have failed first-line treatment with PD-1/PD-L1 inhibitor and a combination regimen containing platinum

Not yet recruiting
4
22
 
Iparomlimab and Tuvonralimab combined with vinorelbine metronomic chemotherapy
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Qilu-pharma
Non-small cell lung cancer
 
 
ChiCTR2500100876: Efficacy and safety of neoadjuvant chemotherapy plus Iparomlimab and Tuvonralimab for locally advanced cervical cancer: A multicenter, randomized, double-blind, parallel-controlled study

Recruiting
4
76
 
Paclitaxel for injection combined with cisplatin chemotherapy and Iparomlimab and Tuvonralimab Injection, for 3 cycles, with 21 days as one cycle; Paclitaxel for injection combined with cisplatin chemotherapy and the simulant of Iparomlimab and Tuvonralimab Injection, for 3 cycles, with 21 days as one cycle
The Seventh Medical Center of Chinese PLA General Hospital; The Seventh Medical Center of Chinese PLA General Hospital, Qilu Pharmaceutical Co., Ltd.
cervical cancer
 
 
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting
3
498
RoW
QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
METASTATIC CERVICAL CANCER
09/24
07/25
QL1706-307, NCT06686576: A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
288
RoW
QL1706, CAPEOX
Qilu Pharmaceutical Co., Ltd.
Colon Cancer
12/30
12/30
NCT06789796: a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not yet recruiting
3
636
NA
Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604, placebo for Iparomlimab and Tuvonralimab (QL1706)
Qilu Pharmaceutical Co., Ltd.
Small-cell Lung Cancer
03/28
03/30
NCT06749899: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
INVIGORATE, NCT07002346: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Not yet recruiting
3
226
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Bevacizumab, carboplatin, Paclitaxel
Tongji Hospital, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center ( FUSCC ), Sun Yat-sen University Cancer Center (SUSUCC), Peking University Cancer Hospital & Institute, Peking University People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, The Second Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Fudan University, Renmin Hospital of Wuhan University, Zhejiang Provincial People's Hospital, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Shanghai First Maternity and Infant Hospital, Hubei Cancer Hospital, Sir Run Run Shaw Hospital, Wuhan Central Hospital, Zhejiang Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, Henan Cancer Hospital, Jiangsu Cancer Institute & Hospital, The International Peace Maternity & Child Health Hospital of China welfare institute, Women's Hospital School Of Medicine Zhejiang University, Wuhan Union Hospital, China, First Affiliated Hospital of Zhejiang University
Ovarian Clear Cell Carcinoma
06/27
06/29
DUBHE-L-303, NCT05690945: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Recruiting
3
608
RoW
QL1706, PSB205, Tilesizumab, BGB-108
Qilu Pharmaceutical Co., Ltd.
Lung Cancer
06/29
12/29
NCT07025239: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Not yet recruiting
3
430
NA
QL1706, Bevacizumab, Oxaliplatin, Capecitabine, Placebo
Qilu Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
07/28
07/29
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Recruiting
3
632
RoW
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
08/27
05/29
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2/3
460
RoW
QL1706, Carrelizumab, Gemcitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/24
12/24
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2/3
668
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab
Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
09/27
09/27
NCT05557565: A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Recruiting
2
150
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Cervical Cancer
10/22
06/23
DUBHE-C-204, NCT05179317: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Active, not recruiting
2
60
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Cervical Cancer
12/22
12/23
DUBHE-L-201, NCT05329025: A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Active, not recruiting
2
100
RoW
QL1706
Qilu Pharmaceutical Co., Ltd.
Non-small-cell Lung Cancer
01/24
01/24
NCT05309629: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Completed
2
40
RoW
QL1706, Carboplatin, Etoposide
Qilu Pharmaceutical Co., Ltd.
Extensive-stage Small-cell Lung Cancer
02/23
12/24
QL1706-IIT-02, NCT05490719: A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Recruiting
2
39
RoW
QL1706, Radiation, Taxol, Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
09/24
09/25
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Recruiting
2
60
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine
Qilu Pharmaceutical Co., Ltd.
Colorectal Carcinoma
03/24
09/25
NCT06313970: First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Not yet recruiting
2
50
NA
QL1706, Nab-paclitaxel, Gemcitabine, Bevacizumab
Fudan University
Pancreatic Cancer
04/25
04/26
QUEEN-Neo, NCT06404463: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting
2
76
NA
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin, Cyclophosphamide, Epirubicin
Fudan University
Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
11/25
11/30
QUEEN-Dream, NCT06404736: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Not yet recruiting
2
73
RoW
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
Fudan University
Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
11/25
11/30
QLS31905-202, NCT06446388: Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting
2
360
RoW
QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
06/26
12/27
NCT06509971: A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Not yet recruiting
2
39
NA
QL1706, bevacizumab, albumin-binding paclitaxel
West China Second University Hospital
Platinum-resistant Recurrent Ovarian Cancer
02/26
06/26
NCT06786026: QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Recruiting
2
60
RoW
bevacizumab, QL1706, Nab paclitaxel
Fudan University
TNBC, Triple Negative Breast Cancer
09/25
12/28
QLMA-EdC-IIT-001, NCT06751277: QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Not yet recruiting
2
26
RoW
QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
xiang yang, Qilu Pharmaceutical Co., Ltd.
Recurrent or Metastatic Endometrial Cancer
12/26
07/27
NCT06750861: QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC

Not yet recruiting
2
30
RoW
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Adenocarcinoma
06/26
12/26
STAR-03, NCT06829797: A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
2
96
NA
Neoadjuvant Therapy(QL1706+SOX Chemotherapy), Neoadjuvant Therapy(SOX Chemotherapy), Radical surgery (D2), Drug: Adjuvant therapy(QL1706+SOX chemotherapy), Drug: Adjuvant therapy(SOX chemotherapy)
Shandong Provincial Hospital
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
02/28
02/28
NCT06942416: Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Recruiting
2
36
RoW
Paclitaxel and Cisplatin/ Carboplatin, Iparomlimab and Tuvonralimab, Radiotherapy
Shandong Cancer Hospital and Institute
Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic
07/26
12/28
QL1706-305, NCT06852456: QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
30
NA
Iparomlimab and Tuvonralimab (QL1706)Injection, Paclitaxel, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
12/30
12/34
Mizar-CC-II-003, NCT06882447: A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Not yet recruiting
2
35
NA
Trial drug: QL1706, HPV 9-valent vaccine
Northern Jiangsu People's Hospital
Cervical Cancer Stage IVB
12/27
12/28
NCT06787183: SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Not yet recruiting
2
42
RoW
Short course radiotherapy, Capecitabine, Oxaliplatin, QL1706
Fujian Cancer Hospital
Locally Advanced Rectal Cancer With Liver Metastases
12/27
12/27
NCT06884982: An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Not yet recruiting
2
30
NA
QL1706 Plus Lenvatinib
Northern Jiangsu People's Hospital
HCC - Hepatocellular Carcinoma
09/27
09/28
QIBA-CER-003, NCT06878222: Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Recruiting
2
35
RoW
Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery, Fertility-preserving surgery
Obstetrics & Gynecology Hospital of Fudan University
Cervical Cancers
03/28
03/30
SEARCH, NCT06932068: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Recruiting
2
77
RoW
Iparomlimab and Tuvonralimab (QL1706), Oxallplation, Capectitabine Tablets
Qilu Hospital of Shandong University
HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
10/26
10/27
NCT06801665: FMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis

Not yet recruiting
2
30
NA
FMT+QL1706+Bevacizumab+XELOX
Hua Jiang
Colon Cancer Liver Metastases
02/27
02/27
NCT06930118: The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Recruiting
2
60
RoW
chidamide, regorafenib, and iparomlimab/tuvonralimab
Shanghai Changzheng Hospital
Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer
04/27
09/27
NCT06908382: Neoadjuvant QL1706 Therapy for ESCC

Recruiting
2
32
RoW
Iparomlimab and Tuvonralimab Injection
Shandong Provincial Hospital
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
12/26
12/28
NCT06911684: Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Recruiting
2
88
RoW
lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
Sun Yat-sen University
Rectal Cancer Patients
04/26
12/31
Spring, NCT06892925: QL1706 Combined with Lenvatinib and GEMOX As First - Line Treatment for Unresectable Biliary Tract Tumors

Not yet recruiting
2
59
RoW
QL1706, Lenvatinib, GEMOX
Eastern Hepatobiliary Surgery Hospital
Biliary Tract Tumors
04/26
04/29
NCT06958484: Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Not yet recruiting
2
60
NA
Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
The Affiliated Hospital of Xuzhou Medical University
HCC - Hepatocellular Carcinoma, Adjuvant Treatment
10/26
12/27
NCT06864013: SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Not yet recruiting
2
116
RoW
Experimental, Control
First Affiliated Hospital of Zhejiang University
Locally Advanced Rectal Cancer (LARC)
12/29
12/29
QLPPEC/GOG-003, NCT06917092: QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

Recruiting
2
30
RoW
QL1706 combined with chemotherapy ± Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Endometrial Adenocarcinoma, Endometrial Cancer
04/27
04/30
NCT06951997: QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Not yet recruiting
2
33
NA
QL1706, Chidamide, Gemcitabine, Nab-paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Metastatic Pancreatic Cancer
05/27
12/27
Neo-Color, NCT06949111: Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（）

Recruiting
2
128
RoW
radiotherapy, CAPOX, Capecitabine, Iparomlimab and Tuvonralimab Injection
Hebei Medical University Fourth Hospital
Colon Cancer
02/27
03/29
NCT06967103: QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Not yet recruiting
2
238
NA
QL1706, Nab-PE
Henan Cancer Hospital
Breast Cancer, HR+/HER2- Breast Cancer
05/27
05/29
NCT07026422: Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Recruiting
2
54
RoW
Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy
Shandong Cancer Hospital and Institute
Rectal Malignant Neoplasms
11/26
05/28
NCT06986057: Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Not yet recruiting
2
28
NA
Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy
Shandong Tumor Hospital
Cervical Cancer, Neoadjuvant Therapy
07/26
12/26
NCT07007728: Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Not yet recruiting
2
54
RoW
Iparomlimab/Tuvonralimab, Bevacizumab + CAPEOX, Surgical resection ± ablation or stereotactic radiotherapy (if applicable)
Peking University Cancer Hospital & Institute
Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
12/26
12/26
NCT07014150: Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Not yet recruiting
2
30
RoW
Lenvatinib, Iparomlimab and Tuvonralimab
Peking Union Medical College Hospital
Hepatocellular Carcinoma Resectable
05/27
05/27
SFRT、RT, NCT06936748: SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

Not yet recruiting
2
30
RoW
Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab
Second Affiliated Hospital of Nanchang University, Qilu Pharmaceutical Co., Ltd.
Cancer
06/28
06/29
NCT07009145: QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Not yet recruiting
2
22
RoW
QL1706, Bevacizumab
Qianfoshan Hospital, Linyi Tumour Hospital, Shandong Provincial Hospital, Qingdao Central Hospital
Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
06/26
12/27
NCT07005583: Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
2
46
RoW
QL1706 Plus Olaparib
Tianjin Medical University Cancer Institute and Hospital
Triple-Negative Breast Cancer (TNBC)
05/27
05/30
NCT06939855: QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
45
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Sun Yat-sen University
Bone and Soft Tissue Tumors
05/27
05/28
NCT07035808: a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .

Not yet recruiting
2
46
NA
2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy
Zhejiang Cancer Hospital, Cancer Hospital of The University of Chinese Academy of Sciences, Cancer Center of the First Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nanchang University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, People's Hospital of Quzhou, First Affiliated Hospital of Ningbo University, Wenzhou Central Hospital, Jinhua Municipal Central Hospital, First Hospital of Zhejiang University, First Affiliated Hospital of Zhejiang University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University
Cervical Cancer Stage IVA, Cervical Cancer Metastatic
12/28
12/29
NCT07041788: Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Not yet recruiting
2
25
RoW
Iparomlimab and Tuvonralimab Injection
Second Affiliated Hospital of Nanchang University, Qilu Pharmaceutical Co., Ltd.
Cancer
07/28
07/30
NCT06897046: Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Not yet recruiting
2
90
NA
QL1706, QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer (NSCLC), II-IIIB
02/27
05/27
QICE-ESCC, NCT07049185: QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
35
NA
QL1706 Plus Celecoxib Group
Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
03/27
09/27
NCT07045805: Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Not yet recruiting
2
66
NA
QL1706 combined with paclitaxel and bevacizumab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Gastric Cancer (GC)
07/27
03/28
CCGLC-017, NCT06954116: Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Not yet recruiting
2
26
RoW
Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
Tongji Hospital, Qilu Pharmaceutical Co., Ltd.
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
12/28
04/29
ChiCTR2500097658: A Single-Center, Single-Arm Clinical Study of Iparomlimab and Tuvonralimab Injection as Monotherapy for Advanced Hepatocellular Carcinoma Beyond first-Line Therapy

Not yet recruiting
2
30
 
Q3W, QL1706 at a dose of 5mg/kg is administered on the first day of each cycle. The dosing time window can be ±3 days. However, within 72 hours before each administration, except for imaging examinations, the subjects must complete all the examinations including vital signs, physical examination, laboratory tests, and ECOG PS score.
Taixing People's Hospital; Taixing People's Hospital, Self-finance
Hepatocellular carcinoma
 
 
ChiCTR2500096704: Iparomlimab/tuvonralimab combined with regorafenib for first-line failure of rare tumors of the digestive system

Not yet recruiting
2
91
 
Iparomlimab/tuvonralimab，regorafenib; Iparomlimab/tuvonralimab,regorafenib; Iparomlimab/tuvonralimab,regorafenib
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-raised
Advanced rare gastrointestinal tumors (anal squamous cell carcinoma, peritoneal mesothelioma, and peritoneal metastatic cancer) that have failed first-line or above treatment
 
 
ChiCTR2500103154: Clinical study on the treatment of advanced melanoma with Iparomlimab and Tuvonralimab combined with chemotherapy and bevacizumab

Not yet recruiting
2
26
 
Iparomlimab and Tuvonralimab+albumin-bound paclitaxel + carboplatin + bevacizumab
Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Self-raised
Melanoma
 
 
ChiCTR2500101134: Iparomlimab and tuvonralimab in combination with neoadjuvant chemotherapy in treatment-naive advanced epithelial ovarian cancer: a single-arm, phase II study

Not yet recruiting
2
35
 
Iparomlimab and tuvonralimab antibody combined with TC
Sichuan Cancer Hospital; Sichuan Cancer Hospital, self funded
advanced epithelial ovarian
 
 
ChiCTR2500102923: Iparomlimab and Tuvonralimab Injection in combination with nab-paclitaxel and carboplatin for the treatment of inoperable or recurrent metastatic treatment-naive thymic carcinoma prospective, single-arm, phase II exploratory study

Not yet recruiting
2
40
 
Immunotherapy + chemotherapy
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute), Self-selected project (self-raised)
Inoperable or recurrent and metastatic newly diagnosed thymic carcinoma
 
 
ChiCTR2500101129: ​Efficacy and Safety of Iparomlimab/Tuvorlimab (QL1706) in Treating Intermediate Trophoblastic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial​​

Not yet recruiting
2
20
 
QL1706; QL1706 plus chemotherapy
Peking Union Medical College Hospital; Peking Union Medical College Hospital, National Key R&D Program (China)​​
Intermediate trophoblastic tumors
 
 
ChiCTR2500103468: A single-arm, multicenter, phase II clinical study of Tuvonralimab/Iparomlimab and docetaxel in patients with advanced non-small-cell lung cancer who have progressed following immune checkpoint inhibitor

Not yet recruiting
2
43
 
Treated with Otto combination antibody (5 mg/kg) plus docetaxel (60-75 mg/m2) every 3 weeks (Q3W)
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Projects entrusted by enterprises and public institutions
Non-small-cell lung cancer
 
 
ChiCTR2500102974: A single arm, single center study to explore the efficacy and safety of Iparomlimab and Tuvonralimab Injection plus Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2
24
 
Iparomlimab and Tuvonralimab Injection
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Self-financed
Triple Negative Breast Cancer (TNBC)
 
 
ChiCTR2500102587: Iparomlimab and Tuvonralimab as second-line treatment in recurrent/metastatic squamous cell carcinoma of the head and neck: a prospective, single-arm, phase II clinical study

Not yet recruiting
2
34
 
Iparomlimab and Tuvonralimab, 5mg/kg,q3w
Pingxiang People's Hospital; Pingxiang People's Hospital, Qilu Pharmaceutical Co., Ltd.
Recurrent/metastatic squamous cell carcinoma of the head and neck
 
 
ChiCTR2500103181: A single-arm phase II multicenter clinical study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab in the first-line treatment of MSI-H/dMMR or POLE/POLD1 mutated metastatic colorectal cancer

Not yet recruiting
2
55
 
Iparomlimab and Tuvonralimab Injection; Iparomlimab and Tuvonralimab Injection
Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, Subject of your choice (self-supporting)
Metastatic colorectal cancer with MSI-H/dMMR or POLE/POLD1 mutations
 
 
NCT05262413: A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Not yet recruiting
1/2
60
NA
QL1706 Plus Lenvatinib, PSB205
Qilu Pharmaceutical Co., Ltd.
Advanced Renal Cell Carcinoma
07/23
07/24
NCT05603039: A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Recruiting
1/2
80
RoW
QL1706, QL1604, Bevacizumab
Qilu Pharmaceutical Co., Ltd.
Advanced Liver Cancer
12/23
12/23
NCT06746961: Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

Not yet recruiting
1/2
49
NA
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, MK-7902, E7080, LENVIMA
The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
07/26
08/27
NCT06809530: Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Recruiting
1/2
34
RoW
QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta)
Guangzhou Medical University
Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid Tumors
06/26
07/26
QL-GasC-QIBA-1001, NCT06766305: QL1706 Combined With SOX Used in Theperioperative Treatment

Recruiting
1/2
54
RoW
QL1706 combined with SOX
Xiangdong Cheng
Gastric Cancers, Esophagogastric Junction Cancers
02/26
06/31
NCT06941766: Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Recruiting
1/2
20
RoW
QL1706, Chemotherapy
Peking Union Medical College Hospital, Shengjing Hospital, Obstetrics & Gynecology Hospital of Fudan University (Shanghai Red House Ob & Gyn Hospital), Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Henan Cancer Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, The First Affiliated Hospital of Xiamen University, Sichuan Cancer Hospital and Research Institute
Intermediate Trophoblastic Tumor
04/27
04/28
NCT06949761: A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Not yet recruiting
1/2
240
NA
QLC1101+QL1203, QLC1101+QL2107, QLC1101+QL1706, QLC1101+docetaxel
Qilu Pharmaceutical Co., Ltd.
Solid Tumor
09/26
06/27
NCT06602063: Surgery for Relapsed Ovarian Cancer in Precision

Not yet recruiting
1/2
33
RoW
surgery/chemotherapy, Iparomlimab/Tuvonralimab
Shanghai Gynecologic Oncology Group, Shanghai Zhongshan Hospital, Tongji Hospital
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/30
06/30
QL1706-102, NCT05171790: A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

Active, not recruiting
1b
419
RoW
QL1706 injection, PSB205 injection
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/21
12/23
NCT03986606: A Study of PSB205 in Subjects With Advanced Solid Tumors

Recruiting
1
64
US
PSB205
Qilu Puget Sound Biotherapeutics (dba Sound Biologics), Pharmaceutical Research Associates
Neoplasm Malignant
02/21
07/21
NCT04296994: A Study of QL1706 in Subjects With Advanced Malignant Tumor

Active, not recruiting
1
99
RoW
QL1706, PSB205
Qilu Pharmaceutical Co., Ltd.
Advanced Malignant Tumor
12/21
12/23
QLMA-HCC-IIT-101, NCT06822985: QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Not yet recruiting
1
21
RoW
QL1706
Wan-Guang Zhang, Qilu Pharmaceutical Co., Ltd.
HCC - Hepatocellular Carcinoma
08/26
08/26
NCT06931873: Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer

Not yet recruiting
1
60
NA
SCRT+Capoex+QL706, LCRT+Capoex+QL706
Changhai Hospital
Rectal Cancer
03/28
03/35
NCT06760676: A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Not yet recruiting
1
90
NA
Pulsed low dose rate radiotherapy (PLDR), Alpaloritovorelli antibodies
Anhui Provincial Hospital, Qilu Pharmaceutical Co., Ltd.
Esophageal Cancer, Non Small Cell Lung Cancer, Cervical Cancer
05/27
07/27
ChiCTR2500101088: A Prospective, Open-label, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Injection +- TKI Agents in Advanced Hepatocellular Carcinoma Patients Previously Treated with Immune Checkpoint Inhibitors

Not yet recruiting
1
20
 
paromlimab and Tuvonralimab Injection:5mg/kg, on day 1 , day 21 of each cycle ; Tyrosine kinase inhibitors (TKIs): Administration at the investigator's discretion.
Huaibei People's Hospital; Huaibei People's Hospital, Self-funded
Hepatocellular carcinoma
 
 
ChiCTR2500103253: An Open-label, Single-arm, Single-center Clinical Study of Iparomlimab and Tuvorralimab (QL1706) in Combination with Lenvatinib as First-line Treatment for Hepatocellular Carcinoma (HCC)

Not yet recruiting
1
30
 
paromlimab and Tuvonralimab Injection:5mg/kg, on day 1 , day 21 of each cycle ; Lenvatinib: oral, once a day, based on patient's weight (<=60 kg: 8 mg; >60 kg: 12 mg).
The First Affiliated Hospital of Anhui University of Technology; The First Affiliated Hospital of Anhui University of Technology, Self-funded
Hepatocellular carcinoma
 
 
ICT-HCC, NCT06893887: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
FOLFOX4, Adebrelimab, Apatinib, Icaritin, SHR-1701, QL1706, Bevacizumab, HAIC, Local treatment, The original treatment regimen
Nanjing Tianyinshan Hospital
Hepatocellular Carcinoma(HCC)
03/27
03/28
NCT07046780: A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Not yet recruiting
N/A
90
RoW
Observation arm
PENG YUAN
Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
07/27
12/27
ChiCTR2500099628: Efficacy and safety evaluation of Iparomlimab and Tuvonralimab combined with Anlotinib in treatment of small-cell lung cancer for second-line and above: A Single Arm, Single-Center, Open-Label Trial.

Not yet recruiting
N/A
35
 
the combination antibody of Iparomlimab and Tuvonralimab at a dose of 5 mg/kg is administered intravenously once every three weeks, in combination with Anlotinib taken orally at 12 mg/day for 14 days, repeated every three weeks.
The Second Affiliated Hospital of Zhejiang University School of Medicine; the department of respiratory medicine, Qilu Pharmaceutical Co., Ltd.
Lung cancer
 
 
ChiCTR2500099552: Clinical study of short-term radiotherapy followed by Iparomlimab and Tuvonralimab Injection combined with TAS-102 (Suyuan) and oxaliplatin neoadjuvant therapy for locally advanced rectal cancer

Not yet recruiting
N/A
30
 
SBRT+ Iparomlimab and Tuvonralimab Injection +TAS-102 + oxaliplatin
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Qilu Pharmaceutical Co., Ltd
Rectal cancer
 
 
ChiCTR2500095948: A single-arm, open-label, multicenter clinical study of Aplalitovorali (QL1706, anti-PD1/CTLA-4 combination antibody) in combination with chemotherapy for the treatment of recurrent or metastatic endometrial cancer

Not yet recruiting
N/A
26
 
Atezo combination antibody combined with chemotherapy
Peking Union Medical College Hospital; Peking Union Medical College Hospital, A single-arm, open-label, multicenter clinical study of Aplalitovorali (QL1706, anti-PD1/CTLA-4 comb
Newly diagnosed recurrent or metastatic endometrial cancer.
 
 
ChiCTR2500102918: Neo-adjuvant QL1706 combined with chemotherapy for stage II-III non-small cell lung cancer(NSCLC): A single-arm, phase II study

Not yet recruiting
N/A
30
 
QL1706 (5mg/kg, iv, q3w) combined with chemotherapy as neo-adjuvant treatment for three cycles
Zhangzhou Municipal Hospital of Fujian Province; Zhangzhou Municipal Hospital of Fujian Province, Qilu Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2500101828: A real-world study on the treatment of advanced first-line gastric / esophageal cancer with low expression of PD-L1 with Iparomlimab and Tuvonralimab Injection

Not yet recruiting
N/A
200
 
None; None
Henan Cancer Hospital; Henan Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Gastric / esophageal cancer
 
 
ChiCTR2500101824: A real-world study of Iparomlimab and Tuvonralimab in the treatment of digestive tract tumors after previous first-line immunotherapy resistance

Recruiting
N/A
148
 
None
Henan Cancer Hospital; Henan Cancer Hospital, Qilu Pharmaceutical Co., Ltd
Gastrointestinal cancer
 
 
ChiCTR2500102269: QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Not yet recruiting
N/A
580
 
PD-1/CTLA-4 bi-specific Antibody combined with chemoradiotherapy; induction chemotherapy followed by systemic therapy/RT
Sun Yat-sen University Cancer Prevention and Treatment Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen University Cancer Prevention and Treatment Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Research Institute), Self-selected topic (self-sponsored)
Advanced nasopharyngeal carcinoma in a high-risk localized area
 
 
PSB202 / Sound Biologics
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Recruiting
1a/1b
110
US, RoW
PSB202
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
07/23
01/24

Download Options